Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 14
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL), GELLC-7 trial from the Spanish group of CLL (GELLC)

  • Abrisqueta, Pau|||0000-0001-9625-7422
  • González Barca, Eva|||0000-0002-1323-1508
  • Ferrá, Christelle|||0000-0003-4571-5125
  • Ríos-Herranz, Eduardo
  • Fernández de la Mata, Margarita
  • Delgado, Julio|||0000-0002-5157-4376
  • Andreu, Rafael|||0000-0002-9220-3352
  • Hernández-Rivas, José Ángel
  • Terol, María José
  • Navarro, Almudena
  • Vidriales, M. Belén
  • Baltasar, Patricia
  • De La Serna, Javier|||0000-0003-3904-1101
  • Ramírez, Á.ngel
  • Ballester, C.
  • Moreno, Carol|||0000-0003-3275-0271
  • García-Marco, J.A.|||0000-0002-8993-5982
  • Córdoba, Raúl|||0000-0002-7654-8836
  • Yáñez, Lucrecia|||0000-0001-9925-3048
  • Casado, Luis Felipe
  • González, Marcos
  • Bosch Albareda, Francesc|||0000-0001-9241-2886
BTK inhibitors have been concurrently administered with anti-CD20 monoclonal antibodies (mAbs) in chronic lymphocytic leukemia (CLL). However, the optimal regimen for combining these two drugs remains pending. Methods: This multi-center phase 2 study aimed to analyze whether consolidation with ofatumumab improved the response in patients with CLL receiving front-line treatment with ibrutinib. Patients received 12 cycles of ibrutinib monotherapy. Those who achieved CR after this induction were maintained on ibrutinib. Conversely, those who did not attain CR continued with ibrutinib in addition to a consolidation, which involved 7 doses of ofatumumab. The primary objective was the complete response (CR) rate at cycle 20. This study is registered within the EU Clinical Trials Register (EudraCT 2016-004937-26). Findings: Between September 8, 2017, and May 21, 2018, 84 patients (median age, 69 years) were included. After completion of 12 cycles of ibrutinib (n = 80), 4 patients (5%) were in CR, 67 (84%) in partial response (PR), and 6 patients (7%) had a PR with lymphocytosis (PRL). After consolidation with ofatumumab, 20 patients improved the response from PR to CR and 6 patients with PRL obtained a PR. Seventy-one patients (85%) completed 20 cycles of treatment, with a CR rate of 24/71 (34%). According to the intention-to-treat analysis at cycle 20, the ORR was 69/84 (82.2%), with a CRR of 24/84 (28.6%). Progression-free survival and overall survival at 48-months were 89.9% (CI: 82.4-95.5) and 92.2% (CI: 85.3-97.1), respectively. Interpretation: These findings underscore the potential for a consolidation strategy in CLL, wherein the addition of a mAb in patients with low tumor burden might enhance the quality of the response. Funding: The study was funded by Janssen that also supplied ibrutinib, whereas ofatumumab was supplied by Novartis.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Expanding the Diversity at the C-4 Position of Pyrido[2,3-d]pyrimidin-7(8H)-ones to Achieve Biological Activity against ZAP-70

  • Masip, Victor
  • Lirio, Ángel
  • López-Huertas, Albert
  • Cuenca, Ana Belen
  • Puig de la Bellacasa, Raimon
  • Abrisqueta, Pau
Cross-coupling; Tyrosine kinase inhibitors, Acoblament creuat; Inhibidors de la tirosina quinasa, Acoplamiento cruzado; Inhibidores de la tirosina quinasa, Pyrido[2,3-d]pyrimidin-7(8H)-ones have attracted widespread interest due to their similarity with nitrogenous bases found in DNA and RNA and their potential applicability as tyrosine kinase inhibitors. Such structures, presenting up to five diversity centers, have allowed the synthesis of a wide range of differently substituted compounds; however, the diversity at the C4 position has mostly been limited to a few substituents. In this paper, a general synthetic methodology for the synthesis of 4-substituted-2-(phenylamino)-5,6-dihydropyrido[2,3-d]pyrimidin-7(8H)-ones is described. By using cross-coupling reactions, such as Ullmann, Buchwald–Hartwig, Suzuki–Miyaura, or Sonogashira reactions, catalyzed by Cu or Pd, we were able to describe new potential biologically active compounds. The resulting pyrido[2,3-d]pyrimidin-7(8H)-ones include N-alkyl, N-aryl, O-aryl, S-aryl, aryl, and arylethynyl substituents at C4, which have never been explored in connection with the biological activity of such heterocycles as tyrosine kinase inhibitors, in particular as ZAP-70 inhibitors., This research has been funded by Instituto de Salud Carlos III through the project “PI18/01392” (Co-funded by European Regional Development Fund “A way to make Europe”).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition

  • Jiménez Bernal, Isabel
  • Carabia Juberó, Júlia
  • Bobillo Varela, Sabela
  • Palacio García, Carlos
  • Abrisqueta, Pau
  • Nieto Sáchica, Juan Camilo
  • Castellví Vives, Josep
  • Martínez Ricarte, Francisco Ramón
  • Boix, Joan
  • Purroy Zuriguel, Noelia
  • Puigdefabregas Horta, Lluis
  • Seoane Suarez, Joan
  • Crespo Maull, Marta
  • Pagès Geli, Carlota
  • Bosch, Francesc
XPO1; BTK; Sistema immunitari innat, XPO1; BTK; Sistema inmune innato, XPO1; BTK; Innate immune system, Background Patients diagnosed with primary central nervous system lymphoma (PCNSL) often face dismal outcomes due to the limited availability of therapeutic options. PCNSL cells frequently have deregulated B-cell receptor (BCR) signaling, but clinical responses to its inhibition using ibrutinib have been brief. In this regard, blocking nuclear export by using selinexor, which covalently binds to XPO1, can also inhibit BCR signaling. Selinexor crosses the blood–brain barrier and was recently shown to have clinical activity in a patient with refractory diffuse large B-cell lymphoma in the CNS. We studied selinexor alone or in combination with ibrutinib in pre-clinical mouse models of PCNSL. Methods Orthotopic xenograft models were established by injecting lymphoma cells into the brain parenchyma of athymic mice. Tumor growth was monitored by bioluminescence. Malignant cells and macrophages were studied by immunohistochemistry and flow cytometry. Results Selinexor blocked tumor growth and prolonged survival in a bioluminescent mouse model, while its combination with ibrutinib further increased survival. CNS lymphoma in mice was infiltrated by tumor-promoting M2-like macrophages expressing PD-1 and SIRPα. Interestingly, treatment with selinexor and ibrutinib favored an anti-tumoral immune response by shifting polarization toward inflammatory M1-like and diminishing PD-1 and SIRPα expression in the remaining tumor-promoting M2-like macrophages. Conclusions These data highlight the pathogenic role of the innate immune microenvironment in PCNSL and provide pre-clinical evidence for the development of selinexor and ibrutinib as a new promising therapeutic option with cytotoxic and immunomodulatory potential., This work was supported by research funding from the Instituto de Salud Carlos III, Fondo de Investigaciones Sanitarias (PI17/00950, M.C., PI17/00943, F.B, PI18/01392, P.A., PI16/01278, J.S) cofinanced by the European Regional Development Fund (ERDF); Fundación Asociación Española Contra el Cáncer (M.C. and P.A.) and Gilead Fellowships (GLD16/00144, GLD18/00047, F.B). M.C. holds a contract from Ministerio de Ciencia, Innovación y Universidades (RYC-2012-12018). S.B. is the recipient of a postdoctoral fellowship from Fundación Alfonso Martin Escudero.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

From genetics to therapy: Unraveling the complexities of Richter transformation in chronic lymphocytic leukemia

  • Bosch-Schips, Jan
  • Nadeu, Ferran
  • Cabirta, Alba
  • Abrisqueta, Pau
  • IACOBONI, GLORIA
  • Serna, Angel
  • Bosch, Francesc
Chronic lymphocytic leukemia; Clonal evolution; Richter's transformation, Leucèmia limfocítica crònica; Evolució clonal; Transformació de Richter, Leucemia linfocítica crónica; Evolución clonal; Transformación de Richter, Richter transformation (RT) refers to the progression of chronic lymphocytic leukemia, the most prevalent leukemia among adults, into a highly aggressive lymphoproliferative disorder, primarily a diffuse large B-cell lymphoma. This is a severe complication that continues to be a therapeutic challenge and remains an unmet medical need. Over the last five years, significant advances have occurred in uncovering the biological processes leading to the RT, refining criteria for properly diagnose RT from other entities, and exploring new therapeutic options beyond the ineffective chemotherapy. This review summarizes current knowledge in RT, including recent advances in the understanding of the pathogenesis of RT, in the classification of RT, and in the development of novel therapeutic strategies for this grave complication., This work was supported in part by the Instituto de Salud Carlos III, Fondo de Investigaciones Sanitarias [PI17/00943, F.B, PI18/01392, P.A.], and Gilead Fellowships, United States [GLD18/00047, F.B.] and Fundació la Marató de TV3, Spain [201905-30-31 F.B]. F.N. acknowledges research support from the American Association for Cancer Research (2021 AACR-Amgen Fellowship in Clinical/Translational Cancer Research, 21-40-11-NADE), the European Hematology Association (EHA Junior Research Grant 2021, RG-202012-00245), the Lady Tata Memorial Trust, India (International Award for Research in Leukaemia 2021–2022, LADY_TATA_21_3223).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Immunological and genetic kinetics from diagnosis to clinical progression in chronic lymphocytic leukemia

  • Jiménez Bernal, Isabel
  • Tazón Vega, Bárbara
  • Abrisqueta, Pau
  • Nieto Sáchica, Juan Camilo
  • Bobillo Varela, Sabela
  • Palacio García, Carlos
  • Carabia Juberó, Júlia
  • Munuera Codina, Magdalena
  • Puigdefabregas Horta, Lluis
  • Franco Jarava, Clara
  • Iacoboni García-Calvo, Gloria
  • Crespo Maull, Marta
  • Bosch, Francesc
Progressió clínica; Evasió immune, Progresión clínica; Evasión inmune, Clinical progression; Immune evasion, Background Mechanisms driving the progression of chronic lymphocytic leukemia (CLL) from its early stages are not fully understood. The acquisition of molecular changes at the time of progression has been observed in a small fraction of patients, suggesting that CLL progression is not mainly driven by dynamic clonal evolution. In order to shed light on mechanisms that lead to CLL progression, we investigated longitudinal changes in both the genetic and immunological scenarios. Methods We performed genetic and immunological longitudinal analysis using paired primary samples from untreated CLL patients that underwent clinical progression (sampling at diagnosis and progression) and from patients with stable disease (sampling at diagnosis and at long-term asymptomatic follow-up). Results Molecular analysis showed limited and non-recurrent molecular changes at progression, indicating that clonal evolution is not the main driver of clinical progression. Our analysis of the immune kinetics found an increasingly dysfunctional CD8+ T cell compartment in progressing patients that was not observed in those patients that remained asymptomatic. Specifically, terminally exhausted effector CD8+ T cells (T-betdim/−EomeshiPD1hi) accumulated, while the the co-expression of inhibitory receptors (PD1, CD244 and CD160) increased, along with an altered gene expression profile in T cells only in those patients that progressed. In addition, malignant cells from patients at clinical progression showed enhanced capacity to induce exhaustion-related markers in CD8+ T cells ex vivo mainly through a mechanism dependent on soluble factors including IL-10. Conclusions Altogether, we demonstrate that the interaction with the immune microenvironment plays a key role in clinical progression in CLL, thereby providing a rationale for the use of early immunotherapeutic intervention., This work was supported by the Instituto de Salud Carlos III, Fondo de Investigaciones Sanitarias (PI17/00950, M.C., PI18/01392, P.A. and PI17/00943, F.B.) and co-financed by the European Regional Development Fund (ERDF) and Fundación Asociación Española Contra el Cáncer (M.C. and P.A.), Gilead Fellowships (GLD16/00144, GLD18/00047, F.B.) and Fundació la Marató de TV3 (201905–30-31 F.B). S.B. is the recipient of a postdoctoral fellowship from Fundación Alfonso Martin Escudero. R.V-M. is supported by a Torres Quevedo fellowship from the Spanish Ministry of Science and Innovation (PTQ-16-08623). A.E-C. is funded by ISCIII/MINECO (PT17/0009/0019) which is co-funded by FEDER. M.C. holds a contract from Ministerio de Ciencia, Innovación y Universidades (RYC-2012-2018).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A gene expression assay based on chronic lymphocytic leukemia activation in the microenvironment to predict progression

  • Medina Gil, Daniel
  • Lu, Junyan
  • Alcoceba, Miguel
  • Carabia Juberó, Júlia
  • Boix, Joan
  • Tazón Vega, Bárbara
  • Iacoboni García-Calvo, Gloria
  • Bobillo Varela, Sabela
  • González, Marcos
  • Zenz, Thorsten
  • Crespo Maull, Marta
  • Marin Niebla, Ana
  • Abrisqueta, Pau
  • Bosch, Francesc
  • Villacampa Javierre, Guillermo
Gene expression; Chronic lymphocytic leukemia, Expresión génica; Leucemia linfocítica crónica, Expressió gènica; Leucèmia limfocítica crònica, Several gene expression profiles with a strong correlation with patient outcomes have been previously described in chronic lymphocytic leukemia (CLL), although their applicability as biomarkers in clinical practice has been particularly limited. Here we describe the training and validation of a gene expression signature for predicting early progression in patients with CLL based on the analysis of 200 genes related to microenvironment signaling on the NanoString platform. In the training cohort (n = 154), the CLL15 assay containing a 15-gene signature was associated with the time to first treatment (TtFT) (hazard ratio [HR], 2.83; 95% CI, 2.17-3.68; P < .001). The prognostic value of the CLL15 score (HR, 1.71; 95% CI, 1.15-2.52; P = .007) was further confirmed in an external independent validation cohort (n = 112). Notably, the CLL15 score improved the prognostic capacity over IGHV mutational status and the International Prognostic Score for asymptomatic early-stage (IPS-E) CLL. In multivariate analysis, the CLL15 score (HR, 1.83; 95% CI, 1.32-2.56; P < .001) and the IPS-E CLL (HR, 2.23; 95% CI, 1.59-3.12; P < .001) were independently associated with TtFT. The newly developed and validated CLL15 assay successfully translated previous gene signatures such as the microenvironment signaling into a new gene expression–based assay with prognostic implications in CLL., This work was supported by research funding from the Asociación Española Contra el Cáncer grant [5U01CA157581-05, ECRIN-M3 - A29370] and in part by the Instituto de Salud Carlos III, Fondo de Investigaciones Sanitarias [PI17/00950, M.C., PI17/00943, F.B, PI18/01392, P.A.], and the Spanish Ministry of Economy and Competitiveness [CIBERONC-CB16/12/00233], the Education Council or Health Council of the Junta de Castilla y León [GRS 2036/A/19], and Gilead Sciences [GLD15/00348]. This work was supported by research funding from the Asociación Española Contra el Cáncer grant [5U01CA157581-05, ECRIN-M3 - A29370] and in part by the Instituto de Salud Carlos III, Fondo de Investigaciones Sanitarias [PI17/00950, M.C., PI17/00943, F.B, PI18/01392, P.A.], and the Spanish Ministry of Economy and Competitiveness [CIBERONC-CB16/12/00233], the Education Council or Health Council of the Junta de Castilla y León [GRS 2036/A/19], Gilead Sciences [GLD15/00348] and Gilead Fellowships [GLD16/00144, GLD18/00047, F.B.], and Fundació la Marató de TV3 [201905-30-31 F.B]. All Spanish funding was cosponsored by the European Union FEDER program “Una manera de hacer Europa”. M.C. holds a contract from Ministerio de Ciencia, Innovación y Universidades [RYC-2012-2018].
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition

  • Jiménez, Isabel|||0000-0002-5144-861X
  • Carabia, Júlia
  • Bobillo, Sabela|||0000-0001-7381-680X
  • Palacio-García, Carles|||0000-0002-9085-3327
  • Abrisqueta, Pau|||0000-0001-9625-7422
  • Pagès Geli, Carlota|||0000-0001-9200-3943
  • Nieto Sáchica, Juan Camilo|||0000-0002-3400-1488
  • Castellvi, Josep|||0000-0001-5745-9996
  • Martinez-Ricarte, Fran|||0000-0003-4567-0828
  • Escoda, Lourdes|||0000-0003-3288-9716
  • Perla, Cristóbal
  • Céspedes Torrez, Dennis H.
  • Boix, Joan
  • Purroy i Zuriguel, Noèlia
  • Puigdefàbregas, Lluís
  • Seoane Suárez, Joan|||0000-0002-6541-5974
  • Bosch Albareda, Francesc|||0000-0001-9241-2886
  • Crespo, Marta|||0000-0002-7732-7808
Patients diagnosed with primary central nervous system lymphoma (PCNSL) often face dismal outcomes due to the limited availability of therapeutic options. PCNSL cells frequently have deregulated B-cell receptor (BCR) signaling, but clinical responses to its inhibition using ibrutinib have been brief. In this regard, blocking nuclear export by using selinexor, which covalently binds to XPO1, can also inhibit BCR signaling. Selinexor crosses the blood-brain barrier and was recently shown to have clinical activity in a patient with refractory diffuse large B-cell lymphoma in the CNS. We studied selinexor alone or in combination with ibrutinib in pre-clinical mouse models of PCNSL. Orthotopic xenograft models were established by injecting lymphoma cells into the brain parenchyma of athymic mice. Tumor growth was monitored by bioluminescence. Malignant cells and macrophages were studied by immunohistochemistry and flow cytometry. Selinexor blocked tumor growth and prolonged survival in a bioluminescent mouse model, while its combination with ibrutinib further increased survival. CNS lymphoma in mice was infiltrated by tumor-promoting M2-like macrophages expressing PD-1 and SIRPα. Interestingly, treatment with selinexor and ibrutinib favored an anti-tumoral immune response by shifting polarization toward inflammatory M1-like and diminishing PD-1 and SIRPα expression in the remaining tumor-promoting M2-like macrophages. These data highlight the pathogenic role of the innate immune microenvironment in PCNSL and provide pre-clinical evidence for the development of selinexor and ibrutinib as a new promising therapeutic option with cytotoxic and immunomodulatory potential. The online version of this article (10.1007/s11060-020-03580-y) contains supplementary material, which is available to authorized users.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Immunological and genetic kinetics from diagnosis to clinical progression in chronic lymphocytic leukemia

  • Jiménez, Isabel|||0000-0002-5144-861X
  • Tazón-Vega, Bárbara|||0000-0003-4513-5104
  • Abrisqueta, Pau|||0000-0001-9625-7422
  • Nieto Sáchica, Juan Camilo|||0000-0002-3400-1488
  • Bobillo, Sabela|||0000-0001-7381-680X
  • Palacio-García, Carles|||0000-0002-9085-3327
  • Carabia, Júlia
  • Valdés-Mas, Rafael
  • Munuera, Magdalena
  • Puigdefàbregas, Lluís
  • Parra, Genís
  • Esteve-Codina, Anna|||0000-0003-0361-2873
  • Franco-Jarava, Clara|||0000-0002-9788-189X
  • Iacoboni, Gloria|||0000-0003-0805-9288
  • Terol, María José
  • García-Marco, José Antonio
  • Crespo, Marta|||0000-0002-7732-7808
  • Bosch Albareda, Francesc|||0000-0001-9241-2886
Mechanisms driving the progression of chronic lymphocytic leukemia (CLL) from its early stages are not fully understood. The acquisition of molecular changes at the time of progression has been observed in a small fraction of patients, suggesting that CLL progression is not mainly driven by dynamic clonal evolution. In order to shed light on mechanisms that lead to CLL progression, we investigated longitudinal changes in both the genetic and immunological scenarios. We performed genetic and immunological longitudinal analysis using paired primary samples from untreated CLL patients that underwent clinical progression (sampling at diagnosis and progression) and from patients with stable disease (sampling at diagnosis and at long-term asymptomatic follow-up). Molecular analysis showed limited and non-recurrent molecular changes at progression, indicating that clonal evolution is not the main driver of clinical progression. Our analysis of the immune kinetics found an increasingly dysfunctional CD8 + T cell compartment in progressing patients that was not observed in those patients that remained asymptomatic. Specifically, terminally exhausted effector CD8 + T cells (T-bet dim/- Eomes hi PD1 hi) accumulated, while the the co-expression of inhibitory receptors (PD1, CD244 and CD160) increased, along with an altered gene expression profile in T cells only in those patients that progressed. In addition, malignant cells from patients at clinical progression showed enhanced capacity to induce exhaustion-related markers in CD8 + T cells ex vivo mainly through a mechanism dependent on soluble factors including IL-10. Altogether, we demonstrate that the interaction with the immune microenvironment plays a key role in clinical progression in CLL, thereby providing a rationale for the use of early immunotherapeutic intervention. The online version contains supplementary material available at 10.1186/s40364-021-00290-z.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A gene expression assay based on chronic lymphocytic leukemia activation in the microenvironment to predict progression

  • Abrisqueta, Pau|||0000-0001-9625-7422
  • Medina, Daniel
  • Villacampa Javierre, Guillermo|||0000-0003-4868-6585
  • Lu, Junyan
  • Alcoceba, Miguel|||0000-0002-3819-4846
  • Carabia, Júlia
  • Boix, Joan
  • Tazón-Vega, Barbara
  • Iacoboni, Gloria|||0000-0003-0805-9288
  • Bobillo, Sabela|||0000-0001-7381-680X
  • Marín-Niebla, Ana|||0000-0002-7592-6815
  • González, Marcos
  • Zenz, Thorsten|||0000-0001-7890-9845
  • Crespo Maull, Marta|||0000-0002-7732-7808
  • Bosch Albareda, Francesc|||0000-0001-9241-2886
Several gene expression profiles with a strong correlation with patient outcomes have been previously described in chronic lymphocytic leukemia (CLL), although their applicability as biomarkers in clinical practice has been particularly limited. Here we describe the training and validation of a gene expression signature for predicting early progression in patients with CLL based on the analysis of 200 genes related to microenvironment signaling on the NanoString platform. In the training cohort (n = 154), the CLL15 assay containing a 15-gene signature was associated with the time to first treatment (TtFT) (hazard ratio [HR], 2.83; 95% CI, 2.17-3.68; P <.001). The prognostic value of the CLL15 score (HR, 1.71; 95% CI, 1.15-2.52; P =.007) was further confirmed in an external independent validation cohort (n = 112). Notably, the CLL15 score improved the prognostic capacity over IGHV mutational status and the International Prognostic Score for asymptomatic early-stage (IPS-E) CLL. In multivariate analysis, the CLL15 score (HR, 1.83; 95% CI, 1.32-2.56; P <.001) and the IPS-E CLL (HR, 2.23; 95% CI, 1.59-3.12; P <.001) were independently associated with TtFT. The newly developed and validated CLL15 assay successfully translated previous gene signatures such as the microenvironment signaling into a new gene expression-based assay with prognostic implications in CLL.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

A gene expression assay based on chronic lymphocytic leukemia activation in the microenvironment to predict progression

  • Medina Gil, Daniel
  • Lu, Junyan
  • Alcoceba, Miguel
  • Carabia Juberó, Júlia
  • Boix, Joan
  • Tazón Vega, Bárbara
  • Iacoboni García-Calvo, Gloria
  • Bobillo Varela, Sabela
  • González, Marcos
  • Zenz, Thorsten
  • Crespo Maull, Marta
  • Marin Niebla, Ana
  • Abrisqueta, Pau
  • Bosch, Francesc
  • Villacampa Javierre, Guillermo
Gene expression; Chronic lymphocytic leukemia, Expresión génica; Leucemia linfocítica crónica, Expressió gènica; Leucèmia limfocítica crònica, Several gene expression profiles with a strong correlation with patient outcomes have been previously described in chronic lymphocytic leukemia (CLL), although their applicability as biomarkers in clinical practice has been particularly limited. Here we describe the training and validation of a gene expression signature for predicting early progression in patients with CLL based on the analysis of 200 genes related to microenvironment signaling on the NanoString platform. In the training cohort (n = 154), the CLL15 assay containing a 15-gene signature was associated with the time to first treatment (TtFT) (hazard ratio [HR], 2.83; 95% CI, 2.17-3.68; P < .001). The prognostic value of the CLL15 score (HR, 1.71; 95% CI, 1.15-2.52; P = .007) was further confirmed in an external independent validation cohort (n = 112). Notably, the CLL15 score improved the prognostic capacity over IGHV mutational status and the International Prognostic Score for asymptomatic early-stage (IPS-E) CLL. In multivariate analysis, the CLL15 score (HR, 1.83; 95% CI, 1.32-2.56; P < .001) and the IPS-E CLL (HR, 2.23; 95% CI, 1.59-3.12; P < .001) were independently associated with TtFT. The newly developed and validated CLL15 assay successfully translated previous gene signatures such as the microenvironment signaling into a new gene expression–based assay with prognostic implications in CLL., This work was supported by research funding from the Asociación Española Contra el Cáncer grant [5U01CA157581-05, ECRIN-M3 - A29370] and in part by the Instituto de Salud Carlos III, Fondo de Investigaciones Sanitarias [PI17/00950, M.C., PI17/00943, F.B, PI18/01392, P.A.], and the Spanish Ministry of Economy and Competitiveness [CIBERONC-CB16/12/00233], the Education Council or Health Council of the Junta de Castilla y León [GRS 2036/A/19], and Gilead Sciences [GLD15/00348]. This work was supported by research funding from the Asociación Española Contra el Cáncer grant [5U01CA157581-05, ECRIN-M3 - A29370] and in part by the Instituto de Salud Carlos III, Fondo de Investigaciones Sanitarias [PI17/00950, M.C., PI17/00943, F.B, PI18/01392, P.A.], and the Spanish Ministry of Economy and Competitiveness [CIBERONC-CB16/12/00233], the Education Council or Health Council of the Junta de Castilla y León [GRS 2036/A/19], Gilead Sciences [GLD15/00348] and Gilead Fellowships [GLD16/00144, GLD18/00047, F.B.], and Fundació la Marató de TV3 [201905-30-31 F.B]. All Spanish funding was cosponsored by the European Union FEDER program “Una manera de hacer Europa”. M.C. holds a contract from Ministerio de Ciencia, Innovación y Universidades [RYC-2012-2018].
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Immunological and genetic kinetics from diagnosis to clinical progression in chronic lymphocytic leukemia

  • Jiménez Bernal, Isabel
  • Tazón Vega, Bárbara
  • Abrisqueta, Pau
  • Nieto Sáchica, Juan Camilo
  • Bobillo Varela, Sabela
  • Palacio García, Carlos
  • Carabia Juberó, Júlia
  • Munuera Codina, Magdalena
  • Puigdefabregas Horta, Lluis
  • Franco Jarava, Clara
  • Iacoboni García-Calvo, Gloria
  • Crespo Maull, Marta
  • Bosch, Francesc
Progressió clínica; Evasió immune, Progresión clínica; Evasión inmune, Clinical progression; Immune evasion, Background Mechanisms driving the progression of chronic lymphocytic leukemia (CLL) from its early stages are not fully understood. The acquisition of molecular changes at the time of progression has been observed in a small fraction of patients, suggesting that CLL progression is not mainly driven by dynamic clonal evolution. In order to shed light on mechanisms that lead to CLL progression, we investigated longitudinal changes in both the genetic and immunological scenarios. Methods We performed genetic and immunological longitudinal analysis using paired primary samples from untreated CLL patients that underwent clinical progression (sampling at diagnosis and progression) and from patients with stable disease (sampling at diagnosis and at long-term asymptomatic follow-up). Results Molecular analysis showed limited and non-recurrent molecular changes at progression, indicating that clonal evolution is not the main driver of clinical progression. Our analysis of the immune kinetics found an increasingly dysfunctional CD8+ T cell compartment in progressing patients that was not observed in those patients that remained asymptomatic. Specifically, terminally exhausted effector CD8+ T cells (T-betdim/−EomeshiPD1hi) accumulated, while the the co-expression of inhibitory receptors (PD1, CD244 and CD160) increased, along with an altered gene expression profile in T cells only in those patients that progressed. In addition, malignant cells from patients at clinical progression showed enhanced capacity to induce exhaustion-related markers in CD8+ T cells ex vivo mainly through a mechanism dependent on soluble factors including IL-10. Conclusions Altogether, we demonstrate that the interaction with the immune microenvironment plays a key role in clinical progression in CLL, thereby providing a rationale for the use of early immunotherapeutic intervention., This work was supported by the Instituto de Salud Carlos III, Fondo de Investigaciones Sanitarias (PI17/00950, M.C., PI18/01392, P.A. and PI17/00943, F.B.) and co-financed by the European Regional Development Fund (ERDF) and Fundación Asociación Española Contra el Cáncer (M.C. and P.A.), Gilead Fellowships (GLD16/00144, GLD18/00047, F.B.) and Fundació la Marató de TV3 (201905–30-31 F.B). S.B. is the recipient of a postdoctoral fellowship from Fundación Alfonso Martin Escudero. R.V-M. is supported by a Torres Quevedo fellowship from the Spanish Ministry of Science and Innovation (PTQ-16-08623). A.E-C. is funded by ISCIII/MINECO (PT17/0009/0019) which is co-funded by FEDER. M.C. holds a contract from Ministerio de Ciencia, Innovación y Universidades (RYC-2012-2018).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Expanding the Diversity at the C-4 Position of Pyrido[2,3-d]pyrimidin-7(8H)-ones to Achieve Biological Activity against ZAP-70

  • Masip, Victor
  • Lirio, Ángel
  • López-Huertas, Albert
  • Cuenca, Ana Belen
  • Puig de la Bellacasa, Raimon
  • Abrisqueta, Pau
Cross-coupling; Tyrosine kinase inhibitors, Acoblament creuat; Inhibidors de la tirosina quinasa, Acoplamiento cruzado; Inhibidores de la tirosina quinasa, Pyrido[2,3-d]pyrimidin-7(8H)-ones have attracted widespread interest due to their similarity with nitrogenous bases found in DNA and RNA and their potential applicability as tyrosine kinase inhibitors. Such structures, presenting up to five diversity centers, have allowed the synthesis of a wide range of differently substituted compounds; however, the diversity at the C4 position has mostly been limited to a few substituents. In this paper, a general synthetic methodology for the synthesis of 4-substituted-2-(phenylamino)-5,6-dihydropyrido[2,3-d]pyrimidin-7(8H)-ones is described. By using cross-coupling reactions, such as Ullmann, Buchwald–Hartwig, Suzuki–Miyaura, or Sonogashira reactions, catalyzed by Cu or Pd, we were able to describe new potential biologically active compounds. The resulting pyrido[2,3-d]pyrimidin-7(8H)-ones include N-alkyl, N-aryl, O-aryl, S-aryl, aryl, and arylethynyl substituents at C4, which have never been explored in connection with the biological activity of such heterocycles as tyrosine kinase inhibitors, in particular as ZAP-70 inhibitors., This research has been funded by Instituto de Salud Carlos III through the project “PI18/01392” (Co-funded by European Regional Development Fund “A way to make Europe”).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

From genetics to therapy: Unraveling the complexities of Richter transformation in chronic lymphocytic leukemia

  • Bosch-Schips, Jan
  • Nadeu, Ferran
  • Cabirta, Alba
  • Abrisqueta, Pau
  • IACOBONI, GLORIA
  • Serna, Angel
  • Bosch, Francesc
Chronic lymphocytic leukemia; Clonal evolution; Richter's transformation, Leucèmia limfocítica crònica; Evolució clonal; Transformació de Richter, Leucemia linfocítica crónica; Evolución clonal; Transformación de Richter, Richter transformation (RT) refers to the progression of chronic lymphocytic leukemia, the most prevalent leukemia among adults, into a highly aggressive lymphoproliferative disorder, primarily a diffuse large B-cell lymphoma. This is a severe complication that continues to be a therapeutic challenge and remains an unmet medical need. Over the last five years, significant advances have occurred in uncovering the biological processes leading to the RT, refining criteria for properly diagnose RT from other entities, and exploring new therapeutic options beyond the ineffective chemotherapy. This review summarizes current knowledge in RT, including recent advances in the understanding of the pathogenesis of RT, in the classification of RT, and in the development of novel therapeutic strategies for this grave complication., This work was supported in part by the Instituto de Salud Carlos III, Fondo de Investigaciones Sanitarias [PI17/00943, F.B, PI18/01392, P.A.], and Gilead Fellowships, United States [GLD18/00047, F.B.] and Fundació la Marató de TV3, Spain [201905-30-31 F.B]. F.N. acknowledges research support from the American Association for Cancer Research (2021 AACR-Amgen Fellowship in Clinical/Translational Cancer Research, 21-40-11-NADE), the European Hematology Association (EHA Junior Research Grant 2021, RG-202012-00245), the Lady Tata Memorial Trust, India (International Award for Research in Leukaemia 2021–2022, LADY_TATA_21_3223).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition

  • Jiménez Bernal, Isabel
  • Carabia Juberó, Júlia
  • Bobillo Varela, Sabela
  • Palacio García, Carlos
  • Abrisqueta, Pau
  • Nieto Sáchica, Juan Camilo
  • Castellví Vives, Josep
  • Martínez Ricarte, Francisco Ramón
  • Boix, Joan
  • Purroy Zuriguel, Noelia
  • Puigdefabregas Horta, Lluis
  • Seoane Suarez, Joan
  • Crespo Maull, Marta
  • Pagès Geli, Carlota
  • Bosch, Francesc
XPO1; BTK; Sistema immunitari innat, XPO1; BTK; Sistema inmune innato, XPO1; BTK; Innate immune system, Background Patients diagnosed with primary central nervous system lymphoma (PCNSL) often face dismal outcomes due to the limited availability of therapeutic options. PCNSL cells frequently have deregulated B-cell receptor (BCR) signaling, but clinical responses to its inhibition using ibrutinib have been brief. In this regard, blocking nuclear export by using selinexor, which covalently binds to XPO1, can also inhibit BCR signaling. Selinexor crosses the blood–brain barrier and was recently shown to have clinical activity in a patient with refractory diffuse large B-cell lymphoma in the CNS. We studied selinexor alone or in combination with ibrutinib in pre-clinical mouse models of PCNSL. Methods Orthotopic xenograft models were established by injecting lymphoma cells into the brain parenchyma of athymic mice. Tumor growth was monitored by bioluminescence. Malignant cells and macrophages were studied by immunohistochemistry and flow cytometry. Results Selinexor blocked tumor growth and prolonged survival in a bioluminescent mouse model, while its combination with ibrutinib further increased survival. CNS lymphoma in mice was infiltrated by tumor-promoting M2-like macrophages expressing PD-1 and SIRPα. Interestingly, treatment with selinexor and ibrutinib favored an anti-tumoral immune response by shifting polarization toward inflammatory M1-like and diminishing PD-1 and SIRPα expression in the remaining tumor-promoting M2-like macrophages. Conclusions These data highlight the pathogenic role of the innate immune microenvironment in PCNSL and provide pre-clinical evidence for the development of selinexor and ibrutinib as a new promising therapeutic option with cytotoxic and immunomodulatory potential., This work was supported by research funding from the Instituto de Salud Carlos III, Fondo de Investigaciones Sanitarias (PI17/00950, M.C., PI17/00943, F.B, PI18/01392, P.A., PI16/01278, J.S) cofinanced by the European Regional Development Fund (ERDF); Fundación Asociación Española Contra el Cáncer (M.C. and P.A.) and Gilead Fellowships (GLD16/00144, GLD18/00047, F.B). M.C. holds a contract from Ministerio de Ciencia, Innovación y Universidades (RYC-2012-12018). S.B. is the recipient of a postdoctoral fellowship from Fundación Alfonso Martin Escudero.